133 related articles for article (PubMed ID: 20350281)
21. [HIV disease, antiretroviral treatment and the liver--emerging problems].
Manfredi R
Recenti Prog Med; 2003 Apr; 94(4):149-53. PubMed ID: 12677783
[TBL] [Abstract][Full Text] [Related]
22. [The value of plasma antiretroviral drug monitoring in the management of HIV infected patients].
Tréluyer JM
Ann Med Interne (Paris); 2000 Jun; 151(4):291-6. PubMed ID: 10922957
[TBL] [Abstract][Full Text] [Related]
23. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
[TBL] [Abstract][Full Text] [Related]
24. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
Cressey TR; Lallemant M
Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
[TBL] [Abstract][Full Text] [Related]
26. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.
Warszawski J; Tubiana R; Le Chenadec J; Blanche S; Teglas JP; Dollfus C; Faye A; Burgard M; Rouzioux C; Mandelbrot L;
AIDS; 2008 Jan; 22(2):289-99. PubMed ID: 18097232
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].
Perronne C
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B274-82. PubMed ID: 12180301
[No Abstract] [Full Text] [Related]
28. Predictors of short-term success of antiretroviral therapy in HIV infection.
Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
[TBL] [Abstract][Full Text] [Related]
29. Mortality among urban drug users and the impact of highly active antiretroviral therapy.
Celentano DD
Clin Infect Dis; 2005 Sep; 41(6):873-4. PubMed ID: 16107988
[No Abstract] [Full Text] [Related]
30. [Antiretroviral therapy 2001. Basic principles and current status].
Jablonowski H
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():4-12. PubMed ID: 11373777
[TBL] [Abstract][Full Text] [Related]
31. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
[TBL] [Abstract][Full Text] [Related]
32. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options.
De Luca A; Prosperi M; Bracciale L
Curr Opin HIV AIDS; 2010 Jan; 5(1):27-37. PubMed ID: 20046145
[TBL] [Abstract][Full Text] [Related]
33. The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is 'the more the merrier'?
Martin F; Taylor GP
J Antimicrob Chemother; 2009 Nov; 64(5):895-900. PubMed ID: 19706669
[TBL] [Abstract][Full Text] [Related]
34. [Measurement of the plasma concentration of antiretroviral drugs in HIV therapy].
von Hentig N
Dtsch Med Wochenschr; 2008 Feb; 133(5):191-5. PubMed ID: 18213552
[No Abstract] [Full Text] [Related]
35. Therapeutic drug monitoring.
Martin D
S Afr Med J; 2002 May; 92(5):341-3. PubMed ID: 12108158
[No Abstract] [Full Text] [Related]
36. Antiretroviral therapy for drug users.
Clarke SM; Mulcahy FM
Int J STD AIDS; 2000 Oct; 11(10):627-31. PubMed ID: 11057932
[TBL] [Abstract][Full Text] [Related]
37. What's in a trough? Therapeutic drug monitoring and antiretroviral regimens.
Flexner C
Hopkins HIV Rep; 2000 Jan; 12(1):5, 12. PubMed ID: 11366318
[TBL] [Abstract][Full Text] [Related]
38. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems.
Kumar S; Rao PS; Earla R; Kumar A
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):343-55. PubMed ID: 25539046
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.
McCabe SM; Ma Q; Slish JC; Catanzaro LM; Sheth N; DiCenzo R; Morse GD
Clin Pharmacokinet; 2008; 47(3):153-72. PubMed ID: 18307370
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic drug monitoring in HIV treatment: a literature review.
Wertheimer BZ; Freedberg KA; Walensky RP; Yazdanapah Y; Losina E
HIV Clin Trials; 2006; 7(2):59-69. PubMed ID: 16798621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
